These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21042215)

  • 41. Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols.
    Dolan S; Crombez P; Munoz M
    Eur J Oncol Nurs; 2005; 9 Suppl 1():S14-23. PubMed ID: 16207534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R
    Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NCCN guidelines advocate wider use of colony-stimulating factor.
    McNeil C
    J Natl Cancer Inst; 2005 May; 97(10):710-1. PubMed ID: 15900037
    [No Abstract]   [Full Text] [Related]  

  • 44. [Appropriate use of granulocyte colony-stimulating factor in the management of hematologic malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):694-701. PubMed ID: 25129082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
    Crawford J; Dale DC; Lyman GH
    Cancer; 2004 Jan; 100(2):228-37. PubMed ID: 14716755
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risks and consequences of chemotherapy-induced neutropenia.
    Lyman GH
    Clin Cornerstone; 2006; 8 Suppl 5():S12-8. PubMed ID: 17379159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evidence-based management of neutropenia and fever].
    Ishiguro H; Fung MC; Sakata T; Morizane T; Adachi S
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1365-71. PubMed ID: 14518423
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018).
    Carmona-Bayonas A; Jimenez-Fonseca P; de Castro EM; Mata E; Biosca M; Custodio A; Espinosa J; Vázquez EG; Henao F; Ayala de la Peña F
    Clin Transl Oncol; 2019 Jan; 21(1):75-86. PubMed ID: 30470991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
    Lyman GH; Kuderer NM
    Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Hematopoietic growth factors in the prevention of infections complications in children with hematologic-oncologic diseases].
    Lehrnbecher T
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A88-102. PubMed ID: 11577368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The importance of prophylactic management of chemotherapy-induced neutropenia.
    Repetto L; Accettura C
    Anticancer Drugs; 2003 Oct; 14(9):725-30. PubMed ID: 14551505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.
    Silvestris N; Del Re M; Azzariti A; Maiello E; Lombardi L; Cinieri S; Guarini A; Brunetti AE; Delcuratolo S; De Vita F; Pisconti S; Danesi R; Colucci G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S111-7. PubMed ID: 22443211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Critical appraisal of clinical practice guidelines for adult cancer patients with febrile neutropenia.
    Nasr ZG; Abu Yousef S; Jibril F; Wilby KJ
    Int J Pharm Pract; 2018 Feb; 26(1):49-54. PubMed ID: 28349577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of fever and neutropenia in paediatric cancer patients: room for improvement?
    Haeusler GM; Sung L; Ammann RA; Phillips B
    Curr Opin Infect Dis; 2015 Dec; 28(6):532-8. PubMed ID: 26381997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hematopoietic growth factors in lung cancer.
    Genova C; Rijavec E; Grossi F
    Curr Opin Oncol; 2016 Mar; 28(2):135-44. PubMed ID: 26742020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.